If you haven’t had time to catch-up on all the methods papers published in the last couple of months, here’s our take on the most important covering all aspects of HTA.
Kontodimopoulos N, et al. Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients. The European Journal of Health Economics 2012, DOI: 10.1007/s10198-012-0376-9.
Daniels et al. Second generation endometrial ablation techniques for heavy menstrual bleeding: network meta-analysis. BMJ 2012; 344 doi: 10.1136/bmj.e2564 (Published 23 April 2012)
Chenga et al. A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia. Cancer Treatment Reviews.
Received 30 June 2011. Revised 5 February 2012. Accepted 10 February 2012. Available online 9 March 2012. http://dx.doi.org/10.1016/j.ctrv.2012.02.006
Frederix et al. Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes. Value in Health 2012 Jan;15(1):94-105. Epub 2011 Oct 1.
Bansback N, et al. Using a discrete choice experiment to estimate health state utility values. Journal of Health Economics 2012; Volume 31, Issue 1, Pages 306–318.
Taylor et al. Incorporating Calibrated Model Parameters into Sensitivity Analyses: Deterministic and Probabilistic Approaches. Pharmacoeconomics 2012. 30(2):119-126.
Hawkins N, et al. Surrogates, meta-analysis and cost-effectiveness modelling: a combined analytic approach. Health Economics 2012 Jun;21(6):742-56. doi: 10.1002/hec.1741. Epub 2011 Jul 28.